Market Place
Sourcing Support
Abionyx Pharma Provides an Update on Business for Q3 of 2024
14 Nov 2024 //
INVESTING
ABIONYX Pharma has completed a successful pre-IND the FDA for CER-001
13 Jun 2024 //
BUSINESSWIRE
ABIONYX Acknowledges Results of Phase 3 Study Evaluating CSL112
15 Feb 2024 //
BUSINESSWIRE
ABIONYX Pharma RACERS Study Data in Sepsis Presented at ASN
02 Nov 2023 //
BUSINESSWIRE
ABIONYX RACERS Study in Sepsis Selected for Late-Breaking Results Presentation
16 Oct 2023 //
BUSINESSWIRE
ABIONYX Pharma Announces Its Strategy in Ophthalmology and New +ve Results
31 Mar 2023 //
BUSINESSWIRE
Abionyx hails septic success without dishing data behind claims
17 Jan 2023 //
FIERCE BIOTECH
Abionyx Pharma’s Phase IIa trial of CER-001 for AKI meets primary objective
17 Jan 2023 //
CLINICAL TRIALS ARENA
ABIONYX Reports Positive Results from Phase 2a Pilot Trial Evaluating CER-001
16 Jan 2023 //
BUSINESSWIRE
ABIONYX Pharma Reports Positive Interim Results From Phase 2a Trial of CER-001
07 Apr 2022 //
BUSINESSWIRE
ABIONYX Pharma Receives FDA ODD for CER-001 in LCAT Deficiency
29 Mar 2022 //
BUSINESSWIRE
France`s ANSM Grants Compassionate Access Authorization to Abionyx`s CER-001
03 Jan 2022 //
BUSINESSWIRE
ABIONYX Contributes in Kind to Company of 100% of Capital of IRIS Pharma Holding
06 Dec 2021 //
BUSINESSWIRE
ABIONYX Announces Success of Its Capital Increase in Cash by Private Placement
02 Dec 2021 //
BUSINESSWIRE
ABIONYX Initiates Discussions With IRIS Pharma for Possible Strategic Deal
11 Oct 2021 //
BUSINESSWIRE
ABIONYX Announces Positive Clinical Results From CER-001
02 Mar 2021 //
BUSINESSWIRE
ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Disease
02 Mar 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.